Zymo Research Corporation (Zymo Research), a leader in innovative life science solutions, announced today that it has filed claims in the United District Court for the Central District of California ...

QIAGEN announced earlier in January plans for the repurchase, which comes after QIAGEN returned approximately $300 million to shareholders in early 2024 also through a synthetic share repurchase.

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Qiagen (QGEN – Research Report). The company’s ...

QIAGEN N.V.QGEN and Becton, Dickinson and Company or BD’s BDX joint venture, PreAnalytiX GmbH, recently launched the PAXgene Urine Liquid Biopsy Set.PAXgene will be used for reliable analysis of ...

Kepler Capital analyst Maja Pataki maintained a Hold rating on Qiagen (QGEN – Research Report) on February 6 and set a price target of €42.17.

EPS; adj. operating income margin improves 1.8 percentage points to 28.7% QIAGEN expects the solid growth pace in H2 2024 to continue in 2025. Net sales are expected to rise about 4% CER (and core ...

QIAGEN N.V.’s QGEN long-term business strategy focuses on forming partnerships for the development, commercialization, marketing and distribution of existing and future products. The company ...

10% upside for S&P 500. QIAGEN N.V. (NYSE: QGEN) announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, a leading vaccines and diagnostics supplier to the Brazilian ...